georgie18
2月前
ALLO...$3.31...Fins after todays close...🥳
georgie18
Member Level
Re: georgie18 post# 385280
Wednesday, November 06, 2024 10:27:01 AM
Post#
385286
of 385334
ALLO...$3.22s clearing here...🥳...Looking for the $5.78 Breakout... https://schrts.co/wITCFkcf
georgie18
Member Level
Re: georgie18 post# 663758
Wednesday, November 06, 2024 10:06:32 AM
Post#
663791
of 663807
ALLO...$3.17...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 385240
Wednesday, November 06, 2024 7:12:20 AM
Post#
385251
of 385279
ALLO...$3.10...🥳
georgie18
Member Level
Re: georgie18 post# 663652
Tuesday, November 05, 2024 3:37:32 PM
Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳
georgie18
Member Level
Re: georgie18 post# 385217
Tuesday, November 05, 2024 9:15:04 AM
Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
2月前
ALLO...$3.22s clearing here...🥳...Looking for the $5.78 Breakout... https://schrts.co/wITCFkcf
georgie18
Member Level
Re: georgie18 post# 663758
Wednesday, November 06, 2024 10:06:32 AM
Post#
663791
of 663807
ALLO...$3.17...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 385240
Wednesday, November 06, 2024 7:12:20 AM
Post#
385251
of 385279
ALLO...$3.10...🥳
georgie18
Member Level
Re: georgie18 post# 663652
Tuesday, November 05, 2024 3:37:32 PM
Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳
georgie18
Member Level
Re: georgie18 post# 385217
Tuesday, November 05, 2024 9:15:04 AM
Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
2月前
ALLO...$3.17...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 385240
Wednesday, November 06, 2024 7:12:20 AM
Post#
385251
of 385279
ALLO...$3.10...🥳
georgie18
Member Level
Re: georgie18 post# 663652
Tuesday, November 05, 2024 3:37:32 PM
Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳
georgie18
Member Level
Re: georgie18 post# 385217
Tuesday, November 05, 2024 9:15:04 AM
Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
2月前
ALLO...$3.10...🥳
georgie18
Member Level
Re: georgie18 post# 663652
Tuesday, November 05, 2024 3:37:32 PM
Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳
georgie18
Member Level
Re: georgie18 post# 385217
Tuesday, November 05, 2024 9:15:04 AM
Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
2月前
ALLO...$3 ...starting up again...🥳
georgie18
Member Level
Re: georgie18 post# 385217
Tuesday, November 05, 2024 9:15:04 AM
Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
2月前
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
3月前
ALLO...$3 Hitting again...🥳
georgie18
Member Level
Re: georgie18 post# 41
Friday, September 27, 2024 3:57:49 PM
Post#
42
of 42
ALLO...$2.90...Setting up for the $3 Break again...🥳
georgie18
Member Level
Re: georgie18 post# 658272
Wednesday, September 25, 2024 10:03:06 AM
Post#
659219
of 659662
ALLO...$2.65...added more here on the dip...🥳
georgie18
Member Level
Re: None
Wednesday, September 18, 2024 1:30:50 PM
Post#
40
of 40
ALLO...$2.79 added the dip ...🥳
georgie18
3月前
ALLO...$2.98...W pattern still in play here...Looking for $3.23 Break...🥳off the $2.55 alert...
georgie18
Member Level
Re: georgie18 post# 36
Wednesday, September 11, 2024 4:02:04 PM
Post#
38
of 38
ALLO...$2.92...Psar flipped Bullish...Trying for upper bollie break...🥳...
georgie18
Member Level
Re: georgie18 post# 652456
Monday, August 26, 2024 2:22:57 PM
Post#
655267
of 657175
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳
georgie18
Member Level
Re: georgie18 post# 32
Thursday, August 22, 2024 9:38:16 AM
Post#
33
of 35
ALLO...$2.72s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 652456
Monday, August 19, 2024 3:08:16 PM
Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳
georgie18
Member Level
Re: None
Tuesday, August 06, 2024 1:20:27 PM
Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
georgie18
3月前
ALLO...$2.92...Psar flipped Bullish...Trying for upper bollie break...🥳...
georgie18
Member Level
Re: georgie18 post# 652456
Monday, August 26, 2024 2:22:57 PM
Post#
655267
of 657175
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳
georgie18
Member Level
Re: georgie18 post# 32
Thursday, August 22, 2024 9:38:16 AM
Post#
33
of 35
ALLO...$2.72s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 652456
Monday, August 19, 2024 3:08:16 PM
Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳
georgie18
Member Level
Re: None
Tuesday, August 06, 2024 1:20:27 PM
Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
georgie18
4月前
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳
georgie18
Member Level
Re: georgie18 post# 32
Thursday, August 22, 2024 9:38:16 AM
Post#
33
of 35
ALLO...$2.72s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 652456
Monday, August 19, 2024 3:08:16 PM
Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳
georgie18
Member Level
Re: None
Tuesday, August 06, 2024 1:20:27 PM
Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
Hot Features
プレミアム
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Monksdream
2日前
TrendTrade2016
2月前
Mactheriverrat
2月前
glens0
4月前
NY1972
1年前
jondoeuk
1年前
dmerc
1年前
